Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

75.23 +0.72 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,091,776
Open 74.85
Bid (Size) 74.99 (1)
Ask (Size) 75.29 (4)
Prev. Close 74.51
Today's Range 74.68 - 75.45
52wk Range 72.87 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool

Performance

YTD
-11.90%
-11.90%
1 Month
-3.27%
-3.27%
3 Month
-3.13%
-3.13%
6 Month
-2.22%
-2.22%
1 Year
-12.28%
-12.28%

More News

Read More
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
Stocks Stall On November 21, 2023, As Systematic Flows Abate
Via Talk Markets
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Via Benzinga
Is NASDAQ:GILD suited for dividend investing?
Via Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Via Benzinga
A Closer Look at Gilead Sciences's Options Market Dynamics
Via Benzinga
Where Gilead Sciences Stands With Analysts
Via Benzinga
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
Via Benzinga
Exposures Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
Via Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
Via Investor's Business Daily
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
Via FinancialNewsMedia
Buying the dip in high-yield Gilead Sciences
Via MarketBeat
Exposures COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
Via Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why
Via Benzinga
Gilead Sciences Announces Third Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs
Via Investor's Business Daily
Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity
Via Benzinga
S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.